Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients.Clin Biochem 2007; 40(15):1113-21CB
Abstract
OBJECTIVES
Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines.
DESIGN AND METHODS
A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC-MS/MS.
RESULTS
The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpalpha1).
CONCLUSION
Hpalpha1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of "evidence-based" complementary and alternative medicine.
Links
MeSH
Pub Type(s)
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Validation Studies
Language
eng
PubMed ID
17673196
Citation
Ogawa, Kazuo, et al. "Identification of a Predictive Biomarker for the Beneficial Effect of a Kampo (Japanese Traditional) Medicine Keishibukuryogan in Rheumatoid Arthritis Patients." Clinical Biochemistry, vol. 40, no. 15, 2007, pp. 1113-21.
Ogawa K, Kojima T, Matsumoto C, et al. Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clin Biochem. 2007;40(15):1113-21.
Ogawa, K., Kojima, T., Matsumoto, C., Kamegai, S., Oyama, T., Shibagaki, Y., ... Saiki, I. (2007). Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients. Clinical Biochemistry, 40(15), pp. 1113-21.
Ogawa K, et al. Identification of a Predictive Biomarker for the Beneficial Effect of a Kampo (Japanese Traditional) Medicine Keishibukuryogan in Rheumatoid Arthritis Patients. Clin Biochem. 2007;40(15):1113-21. PubMed PMID: 17673196.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Identification of a predictive biomarker for the beneficial effect of a Kampo (Japanese traditional) medicine keishibukuryogan in rheumatoid arthritis patients.
AU - Ogawa,Kazuo,
AU - Kojima,Tetsuko,
AU - Matsumoto,Chinami,
AU - Kamegai,Satoshi,
AU - Oyama,Takuya,
AU - Shibagaki,Yukari,
AU - Muramoto,Hiroshi,
AU - Kawasaki,Tetsuo,
AU - Fujinaga,Hiroshi,
AU - Takahashi,Kozo,
AU - Hikiami,Hiroaki,
AU - Goto,Hirozo,
AU - Kiga,Chizuru,
AU - Koizumi,Keiichi,
AU - Sakurai,Hiroaki,
AU - Shimada,Yutaka,
AU - Yamamoto,Masahiro,
AU - Terasawa,Katsutoshi,
AU - Takeda,Shuichi,
AU - Saiki,Ikuo,
Y1 - 2007/07/03/
PY - 2007/02/01/received
PY - 2007/05/24/revised
PY - 2007/06/09/accepted
PY - 2007/8/4/pubmed
PY - 2007/12/20/medline
PY - 2007/8/4/entrez
SP - 1113
EP - 21
JF - Clinical biochemistry
JO - Clin. Biochem.
VL - 40
IS - 15
N2 - OBJECTIVES: Kampo (Japanese traditional herbal) medicines are now ethically used in Japan as pharmaceutical grade prescription drugs. However, there are distinct groups of responders and non-responders to Kampo medicines. We searched for biomarker candidates to discriminate responders from non-responders to keishibukuryogan (KBG); one of the most frequently used Kampo medicines. DESIGN AND METHODS: A combination of SELDI technology and a decision tree analysis with proprietary developed bioinformatics tools was applied to 41 (32 for tree construction and 9 for validation test) plasma samples obtained from rheumatoid arthritis (RA) patients. A candidate biomarker protein was identified using LC-MS/MS. RESULTS: The constructed tree with measurable reliability contained only a single peak which was identified as haptoglobin alpha 1 chain (Hpalpha1). CONCLUSION: Hpalpha1 is a biomarker candidate for discriminating responders from non-responders to KBG treatment for RA. The present results may open the way to the establishment of "evidence-based" complementary and alternative medicine.
SN - 0009-9120
UR - https://www.unboundmedicine.com/medline/citation/17673196/Identification_of_a_predictive_biomarker_for_the_beneficial_effect_of_a_Kampo__Japanese_traditional__medicine_keishibukuryogan_in_rheumatoid_arthritis_patients_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0009-9120(07)00252-4
DB - PRIME
DP - Unbound Medicine
ER -
